Related Experiment Video
Updated: Jul 21, 2026

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells
Published on: July 16, 2011
Trends in use, cost, and outcomes of human recombinant erythropoietin, 1989-98
J W Greer1, R A Milam, P W Eggers
1Office of Strategic Planning, Health Care Financing Administration, Baltimore, MD 21244, USA. jgreer@hcfa.gov
Abstract:
In this article the authors present descriptive data showing trends in human recombinant erythropoietin (EPO) doses, charges, and patient hematocrits from the fourth quarter of calendar year 1989 to the first quarter of 1998 for all recipients and recent data for patients treated by in-center hemodialysis. In 1997 nearly all in-center hemodialysis patients received EPO regularly at an average cost per recipient of $6,245 per year for total allowed charges of $842.2 million per year. The study shows that policy changes may have both anticipated and unanticipated effects on medical practice.
More Related Videos
Related Concept Videos
Erythropoiesis
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Erythropoiesis
Factors Affecting Erythropoiesis
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
Continuous Renal Replacement Therapy

